Skip to main content

Table 1 Patient characteristics at inclusion

From: Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort

Variable

Levels

RA patients

RA/SjD patients

All patients

p value

Number of patients

5974

337

6311

 

Age [years]

57 (47, 66)

56 (50, 64)

57 (47, 66)

0.76

Gender

Female

4227 (70.8)

298 (88.4)

4525 (71.1)

< 0.001

Smoker (n = 4171)

Current

1381 (34.9)

51 (23.4)

1432 (34.3)

 
 

Former

1088 (27.5)

59 (27.1)

1147 (27.5)

 
 

Never

1484 (27.5)

108 (49.5)

1592 (38.2)

< 0.001

BMI [kg/m2] (n = 5559)

25.1 (22.2, 28.7)

25.0 (22.5, 28.7)

25.1 (22.2, 28.7)

0.98

Years since RA diagnosis (n = 6190)

2.8 (0.7, 8.4)

4.9 (1.3, 13.2)

2.8 (0.7, 8.6)

< 0.001

CCP (n = 4605)

Positive

2836 (61.6)

201 (70.5)

3037 (62.2)

< 0.001

RF (n = 5772)

Positive

3826 (66.3)

252 (78.0)

4078 (66.9)

< 0.001

Seropositivitya (n = 5889)

4175 (70.9)

271 (82.1)

4446 (71.5)

< 0.001

CRP [mg/l] (n = 3553)

5.0 (2.0, 10.5)

6.0 (2.0, 13.0)

5.0 (2.0, 11.0)

0.29

ESR [mm/h] (n = 5865)

16.0 (8.0, 30.0)

20.0 (10.0, 34.0)

16.0 (8.0, 30.0)

< 0.001

Prior therapy

Corticosteroids

1347 (22.6)

106 (31.4)

1453 (23.0)

< 0.001

 

MTX (n = 6296)

3047 (51.0)

164 (48.7)

3211 (50.9)

0.20

 

LEF (n = 6297)

1030 (17.2)

57 (16.9)

1087 (17.2)

0.01

 

DMARDb

3492 (58.5)

200 (59.4)

3692 (58.5)

0.78

 

TNFi (n = 6307)

1223 (20.5)

78 (23.1)

1301 (20.6)

0.09

 

JAKi

118 (2.0)

5 (1.5)

123 (1.9)

0.69

 

IL-6Ri

234 (3.9)

9 (2.7)

243 (3.9)

0.031

 

Abatacept, RTX (n = 6285)

315 (5.3)

44 (13.1)

359 (5.7)

< 0.001

Number of previous biologics

0

4432 (74.2)

227 (67.4)

4659 (73.8)

 
 

1

1132 (18.9)

76 (22.6)

1208 (19.1)

 
 

2

253 (4.2)

22 (6.5)

275 (4.4)

 
 

≥ 3

157 (2.6)

12 (3.6)

169 (2.7)

0.03

Current therapy

Corticosteroids

2244 (37.6)

157 (46.6)

2401 (38.0)

0.001

 

MTX

3267 (54.7)

175 (51.9)

3442 (54.5)

0.17

 

LEF

882 (14.8)

37 (11.0)

919 (14.6)

0.003

 

TNFi

1556 (26.1)

64 (19.0)

1620 (25.7)

0.003

 

JAKi

147 (2.5)

2 (0.6)

149 (2.4)

0.20

 

IL-6Ri

210 (3.5)

6 (1.8)

216 (3.4)

0.20

 

Abatacept (n = 6284)

183 (61.2)

19 (43.2)

202 (58.9)

< 0.001

 

RTX (n = 6284)

116 (38.8)

25 (56.8)

141 (41.1)

< 0.001

HAQ (n = 5432)

0.8 (0.2, 1.2)

1.0 (0.6, 1.5)

0.8 (0.2, 1.4)

< 0.001

DAS28-CRP (n = 3471)

3.3 (2.2, 4.3)

3.6 (2.4, 4.7)

3.3 (2.2, 4.3)

0.009

DAS28-CRP remissionc (n = 3307)

1055 (31.9)

44 (26.8)

1099 (31.7)

0.20

DAS28-ESR (n = 5781)

3.9 (2.7, 5.0)

4.4 (3.4, 5.4)

3.9 (2.7, 5.0)

< 0.001

Patients globald (n = 5362)

4.0 (2.0, 6.0)

5.0 (3.0, 7.0)

4.0 (2.0, 6.0)

< 0.001

Physicians globald (n = 5253)

3.0 (2.0, 5.0)

4.0 (2.9, 6.0)

3.0 (2.0, 5.0)

0.02

Number of swollen jointse (n = 5754)

4.0 (1.0, 8.0)

5.0 (1.0, 10.0)

4.0 (1.0, 8.0)

< 0.001

Number of tender jointse (n = 5742)

3.0 (0.0, 8.0)

6.0 (1.5, 11.0)

3.0 (0.0, 9.0)

< 0.001

CDAI (n = 4055)

16.0 (8.0, 27.0)

22.5 (14.0, 32.8)

17.0 (8.0, 28.0)

< 0.001

SDAI (n = 1709)

13.3 (6.2, 23.8)

16.2 (7.2, 26.7)

13.4 (6.2, 24.0)

0.25

Ratingen score (n = 4519)

10.0 (4.0, 20.0)

13.0 (6.0, 26.0)

10.0 (4.0, 20.0)

< 0.001

Ultrasound score

GS score (n = 607)

8.0 (4.0, 14.0)

11.0 (7.0, 14.2)

8.0 (5.0, 14.0)

0.08

PD score (n = 561)

1.0 (0.0, 3.0)

3.0 (0.2, 6.0)

1.0 (0.0, 3.0)

0.003

  1. Displayed are n (%) for nominal and median (Q1, Q3) for continuous variables (n = 6311 if not specified)
  2. aPresence of either CCP or RF or both. bTreatment with DMARD. This includes: azathioprine, hydroxychloroquine, cyclosporine, LEF, MTX, sulfasalazine. cRemission defined as DAS28 < 2.6. dVisual analog scale from 0 (best) to 10 (worst). e28 joint count
  3. BMI, body mass index; CCP, CCP-antibody; CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28, disease activity score 28; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; GS, grey scale; HAQ, health assessment questionnaire; IL-6Ri, Interleukin-6-inhibitor; JAKi, Janus kinase-inhibitor; LEF, leflunomide; MTX, methotrexate; PD, power doppler; RA, rheumatoid arthritis; RF, rheumatoid factor; RTX, rituximab; SDAI, simplified disease activity index; SjD, Sjögren’s disease; TNFi, tumour necrosis factor-inhibitor
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us